Swixx BioPharma Consolidates QMS, RIM, and Safety Processes Digital with the CARA Life Sciences Platform
Swixx BioPharma is a one of the largest and fastest-growing dedicated agents for biopharma in the Central, Eastern and South-Eastern regions of Europe and beyond. The organisation will adopt the CARA Life Sciences Platform to transform its processes to digital modes of working, increasing efficiency and thus supporting its exponential growth across the board.
"Finding a vendor with significant experience developing QMS and RIM solutions for clients in the pharmaceutical business was essential for us. We valued Generis' adaptability and desire to collaborate with us to create a solution that will satisfy our requirements on a long run. Because of their flexible solutions, comprehensive approach to master data management, and scalability to incorporate additional GxP-related activities and beyond, Generis became our preferred choice," said Katrin Jones, Regulatory and PV Quality System Director at Swixx.
"Swixx has experienced fast growth in all areas of the business; therefore, to support the expansion of the company, we strive to formalise and standardise our GxP processes with a modern, scalable platform. This will allow us to continue providing first-class services to partners, and proactively prepare for future challenges,"
The CARA Life Sciences Platform provides a solid foundation based on industry standards and regulatory guidelines on which companies can easily configure specialist business processes. In addition, Master Data Management (MDM) offered on the CARA Life Sciences Platform sits on a single information lake, therefore all Regulatory, Quality, and other data is stored in a single repository, streamlining accessibility, traceability, and reuse of that data in other processes across the enterprise.
"The information lake approach offers substantial benefits and has a lot of potential for us. For instance, CARA offers a single interface for all departments and processes so there is no need for additional integrations, and being able to easily reuse our data is an advantage when expanding the Platform use and bringing in other processes," Katrin commented.
"We are delighted to be working with Swixx Biopharma. It underlines for us that the benefits of a scalable platform and consolidating multiple use cases into one system is as beneficial for large multinational pharma companies as for their partners, and we look forward to supporting Swixx in their journey with CARA and ensuring they get the maximum benefit from it," commented James Kelleher, CEO of Generis.
Generis is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis' flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety use cases to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at generiscorp.com
About Swixx BioPharma AG
Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, Russia and several Eurasian countries including Belarus, Kazakhstan, Moldova and Uzbekistan and now the Middle East. With over 1,200 employees and sales set to exceed 900M Euros in 2023, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma in the Central, Eastern and Southeastern regions of Europe and beyond. The company has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com